Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Intangibles (2020 - 2026)

Cytek Biosciences filings provide 6 years of Intangibles readings, the most recent being $16.8 million for Q4 2025.

  • On a quarterly basis, Intangibles fell 16.43% to $16.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.8 million, a 16.43% decrease, with the full-year FY2025 number at $16.8 million, down 16.43% from a year prior.
  • Intangibles hit $16.8 million in Q4 2025 for Cytek Biosciences, down from $17.7 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $24.7 million in Q1 2023 to a low of $333000.0 in Q2 2021.
  • Median Intangibles over the past 5 years was $18.6 million (2025), compared with a mean of $14.5 million.
  • Biggest five-year swings in Intangibles: soared 1629.56% in 2021 and later fell 16.43% in 2025.
  • Cytek Biosciences' Intangibles stood at $4.7 million in 2021, then decreased by 8.61% to $4.3 million in 2022, then skyrocketed by 432.99% to $23.1 million in 2023, then fell by 12.81% to $20.1 million in 2024, then fell by 16.43% to $16.8 million in 2025.
  • The last three reported values for Intangibles were $16.8 million (Q4 2025), $17.7 million (Q3 2025), and $18.6 million (Q2 2025) per Business Quant data.